Atazanavir, sold under the trade name Reyataz among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. It is taken by mouth once a day.

The global Atazanavir market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Atazanavir volume and value at global level, regional level and company level. From a global perspective, this report represents overall Atazanavir market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Atazanavir in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Atazanavir manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Bristol-Myers Squibb
TEVA
Cipla
Mylan
Aurobindo Pharma
Emcure
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
150 mg capsule
200 mg capsule
300 mg capsule
50 mg oral powder packet

Segment by Application
Adults
Children 3 months of age and older